Nuvectis Pharma
NVCT· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +39.6% in FY2025
Ron Bentsur is the CEO of Nuvectis Pharma and was paid $2.6M in FY2025 (Dec), up 124%.
Pay$100 in the stock at the end of FY22 → $101
Executives3
See all- 1Ron BentsurChairman & CEOFY2025
- 2Enrique PoradosuChief Scientific & Business OfficerFY2025
- 3Shay ShemeshChief Development and Operations OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allNuvectis Pharma paid its 3 named executives $5.8M in total in FY2025 (Dec). CEO Ron Bentsur was paid $2.6M of that.
| Name | |||
|---|---|---|---|
| Ron BentsurChairman & CEO | |||
| Enrique PoradosuChief Scientific & Business Officer | |||
| Shay ShemeshChief Development and Operations Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Nuvectis Pharma. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board1
See all- Kenneth HobermanDirector · 4 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 27, 2026 | FY2025 |
| Annual report | 10-K | Feb 11, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Feb 25, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 29, 2024 | FY2023 |
| Annual report | 10-K | Mar 5, 2024 | FY2023 |
